Lung Neuroendocrine Neoplasm clinical trials at UCSF
2 in progress, 1 open to eligible people
Lung neuroendocrine neoplasms are cancers that develop in the lung's hormone-producing cells. UCSF is testing a new treatment called Lutetium Lu 177 Dotatate on these tumors. Researchers are comparing this approach to the usual treatments to evaluate its effectiveness.
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
open to eligible people ages 18 years and up
This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced). Lutetium Lu 177-dotate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Lutetium Lu 177 dotatate may be more effective than everolimus in shrinking or stabilizing advanced bronchial neuroendocrine tumors.
San Francisco, California and other locations
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Sorry, in progress, not accepting new patients
This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.
San Francisco, California and other locations
Our lead scientists for Lung Neuroendocrine Neoplasm research studies include Claire Mulvey.
Last updated: